Kuehn Law Encourages Investors of Actinium Pharmaceuticals, Inc. to Contact Law Firm

Core Viewpoint - Kuehn Law, PLLC is investigating potential breaches of fiduciary duties by certain officers and directors of Actinium Pharmaceuticals, Inc. related to misrepresentation of clinical trial data and its implications for FDA approval of Iomab-B BLA [1][2]. Group 1: Legal Investigation - Kuehn Law is looking into whether Actinium Pharmaceuticals' officers and directors failed to fulfill their fiduciary responsibilities to shareholders [1]. - The investigation stems from a federal securities lawsuit alleging that insiders misrepresented or failed to disclose critical information regarding the Sierra Trial data and its compliance with FDA guidelines [2]. Group 2: FDA Approval Concerns - The lawsuit claims that the data from the Sierra Trial is unlikely to meet FDA standards for the acceptance and approval of Iomab-B BLA [2]. - Additional analyses provided to the FDA, which were intended to show improved Overall Survival, are also said to be insufficient for FDA approval [2]. - As a result of these issues, the FDA may refuse to review the Iomab-B BLA or find it unlikely to approve the application in its current form [2]. Group 3: Shareholder Implications - Positive statements made by the company regarding its business and prospects are alleged to be materially misleading and lack a reasonable basis due to the aforementioned issues [2]. - Shareholders who purchased ATNM shares prior to October 31, 2022, are encouraged to contact Kuehn Law for potential legal recourse [3].